AllerGene AI Therapeutics is a biotechnology company building first-in-class in vivo mRNA-LNP CAR-T therapies targeting disease-driving mast cells, with the potential to transform the treatment of mast cell diseases, chronic urticaria, food allergies, asthma, and life-threatening anaphylaxis. We are seeking seed funding to accelerate our development towards the clinic.